Simon Lennartz
Research Subjects
Research Interests
Simon Lennartz has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Andre Gosselink
Institute of Medical Statistics and Computational Biology Faculty of Medicine University of Cologne Cologne Germany
1 shared publication Andrew D. Kaiser
Miltenyi Biotec B.V. & Co. KG
1 shared publicationBettina Kotter
Miltenyi Biotec B.V. & Co. KG
1 shared publication- Brian Webster
CIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, France
1 shared publication Carolin Kolbe
Miltenyi Biotec B.V. & Co. KG
1 shared publication- Daniel Schaefer
Miltenyi Biotec B.V. & Co. KG
1 shared publication
Latest Publications
- Open Access
- 11 November 2022
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2140534
Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells
Solid tumors consist of malignant and nonmalignant cells that together create the local tumor microenvironment (TME). Additionally, the TME is characterized by the expression of numerous soluble factors such as TGF-β. TGF-β plays an important role in the TME by suppressing T cell effector function and promoting tumor invasiveness. Up to now CAR T cells exclusively target tumor-associated antigens (TAA) located on the cell membrane. Thus, strategies to exploit soluble antigens as CAR targets within the TME are needed. This study demonstrates a novel approach using Adapter CAR (AdCAR) T cells for the detection of soluble latent TGF-β within the TME of a pancreatic tumor model. We show that AdCARs in combination with the respective adapter can be used to sense soluble tumor-derived latent TGF-β, both in vitro and in vivo. Sensing of the soluble antigen induced cellular activation and effector cytokine production in AdCAR T cells. Moreover, we evaluated AdCAR T cells for the combined targeting of soluble latent TGF-β and tumor cell killing by targeting CD66c as TAA in vivo. In sum, our study broadens the spectrum of targetable moieties for AdCAR T cells by soluble latent TGF-β.
- 11 November 2022
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2140534
Open AccessCombined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells
Solid tumors consist of malignant and nonmalignant cells that together create the local tumor microenvironment (TME). Additionally, the TME is characterized by the expression of numerous soluble factors such as TGF-β. TGF-β plays an important role in the TME by suppressing T cell effector function and promoting tumor invasiveness. Up to now CAR T cells exclusively target tumor-associated antigens (TAA) located on the cell membrane. Thus, strategies to exploit soluble antigens as CAR targets within the TME are needed. This study demonstrates a novel approach using Adapter CAR (AdCAR) T cells for the detection of soluble latent TGF-β within the TME of a pancreatic tumor model. We show that AdCARs in combination with the respective adapter can be used to sense soluble tumor-derived latent TGF-β, both in vitro and in vivo. Sensing of the soluble antigen induced cellular activation and effector cytokine production in AdCAR T cells. Moreover, we evaluated AdCAR T cells for the combined targeting of soluble latent TGF-β and tumor cell killing by targeting CD66c as TAA in vivo. In sum, our study broadens the spectrum of targetable moieties for AdCAR T cells by soluble latent TGF-β.